» Articles » PMID: 9626119

A Defect in Renal Calcium Conservation May Contribute to the Pathogenesis of Postmenopausal Osteoporosis

Overview
Specialty Endocrinology
Date 1998 Jun 17
PMID 9626119
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Although all postmenopausal women are estrogen deficient, women who have postmenopausal osteoporosis may have a defect, in addition to estrogen deficiency, that accounts for their higher rates of bone resorption and greater bone loss, relative to those who do not. To test the hypothesis that one defect is an impairment in renal calcium conservation, we measured renal calcium transport in 19 osteoporotic and 19 normal postmenopausal women, whose ages (median and 25th-75th percentile range) were 70 yr (range, 67-72) and 72 yr (range, 69-74), respectively. There was no difference between groups in values for serum ionized calcium and PTH concentrations or in renal filtered load of calcium. However, before PTH infusion, the osteoporotic women had lower (P = 0.0046) values for tubular reabsorption of calcium (TRCa) of 96.8% (range, 96.0-97.1) vs. 98.0% (range, 97.2-98.3) and higher (P = 0.0154) urinary calcium excretion of 0.194 mg/dL of glomerular filtrate (GF) (0.154-0.239) vs. 0.125 mg/dL of GF (0.103-0.173) than the normal women. After infusion of 200 U of synthetic PTH (synthetic 1-34 analog of human PTH), TRCa increased and calcium excretion decreased comparably in both groups, so that the differences between groups after intervention remained: for TRCa, 98.3% (97.7-98.6) vs. 98.9% (98.4-99.3; P = 0.0042); and for calcium excretion, 0.099 mg/dL of GF (0.080-0.138) vs. 0.066 mg/dL of GF, (0.045-0.097, P = 0.0180). In conclusion, postmenopausal women with osteoporosis have a PTH-independent defect in renal calcium conservation. This defect is of sufficient magnitude to contribute to the greater negative calcium balance in post-menopausal women with osteoporosis vs. their postmenopausal peers.

Citing Articles

Interrelationships among metabolic syndrome, bone-derived cytokines, and the most common metabolic syndrome-related diseases negatively affecting bone quality.

Martiniakova M, Mondockova V, Kovacova V, Babikova M, Zemanova N, Biro R Diabetol Metab Syndr. 2024; 16(1):217.

PMID: 39238022 PMC: 11378428. DOI: 10.1186/s13098-024-01440-7.


Thiazide use and skeletal microstructure: Results from a multi-ethnic study.

Huynh H, Fan L, Germosen C, Bucovsky M, Colon I, Kil N Bone Rep. 2022; 16:101589.

PMID: 35601882 PMC: 9121265. DOI: 10.1016/j.bonr.2022.101589.


In Silico Network Analysis of Ingredients of Cornus officinalis in Osteoporosis.

Huang F, Guo H, Wei Y, Zhao X, Chen Y, Lin Z Med Sci Monit. 2021; 27:e929219.

PMID: 33795629 PMC: 8023278. DOI: 10.12659/MSM.929219.


Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits.

Thrailkill K, Bunn R, Uppuganti S, Ray P, Popescu I, Kalaitzoglou E Bone. 2020; 141:115625.

PMID: 32890778 PMC: 7852344. DOI: 10.1016/j.bone.2020.115625.


Effectiveness of thiazides on serum and urinary calcium levels and bone mineral density in patients with osteoporosis: a systematic review and meta-analysis.

Cheng L, Zhang K, Zhang Z Drug Des Devel Ther. 2018; 12:3929-3935.

PMID: 30532521 PMC: 6241760. DOI: 10.2147/DDDT.S179568.